Table 1.
Receptor antibodies before/after vaccination and in PACVS.
| Median 1 | 25% Perc. | 75% Perc. | ∆ vs. PACVS (p, U-Test) |
|
|---|---|---|---|---|
| AT1R | ||||
| PACVS 2 (n = 191) | 15.2 | 12.1 | 21.3 | - |
| Contr. pre 3 (n = 89) | 15.6 | 12.4 | 21.1 | N.S. 5 |
| Contr. post 4 (n = 89) | 10.4 | 8.1 | 12.4 | <0.0001 |
| ETAR | ||||
| PACVS (n = 191) | 13.5 | 10.8 | 18.5 | - |
| Contr. pre (n = 99) | 15.4 | 11.6 | 19.5 | N.S. |
| Contr. post (n = 89) | 11.0 | 8.8 | 13.8 | 0.0001 |
| IL-1-Rb | ||||
| PACVS (n = 191) | 4.9 | 3.8 | 6.9 | - |
| Contr. pre (n = 89) | 5.1 | 4.2 | 7.2 | N.S. |
| Contr. post (n = 89) | 6.2 | 5.3 | 8.2 | <0.0001 |
| M3R | ||||
| PACVS (n = 191) | 10.6 | 7.9 | 16.4 | - |
| Contr. pre (n = 89) | 11.9 | 8.0 | 18.2 | N.S. |
| Contr. post (n = 89) | 6.6 | 4.8 | 9.2 | <0.0001 |
| β2-adr-R | ||||
| PACVS (n = 191) | 12.8 | 8.9 | 16.6 | - |
| Contr. pre (n = 89) | 20.9 | 11.2 | 39.6 | N.S. |
| Contr. post (n = 89) | 9.3 | 5.8 | 14.4 | <0.0001 |
| MASR | ||||
| PACVS (n = 191) | 50.2 | 41.7 | 62.1 | - |
| Contr. pre (n = 89) | 53.1 | 42.8 | 67.6 | N.S. |
| Contr. post (n = 89) | 39.2 | 31.7 | 45.7 | <0.0001 |
| M2R | ||||
| PACVS (n = 191) | 11.8 | 8.9 | 16.9 | - |
| Contr. pre (n = 89) | 16.9 | 11.3 | 27.2 | <0.0001 |
| Contr. post (n = 89) | 7.7 | 6.2 | 11.7 | <0.0001 |
| α2b-adr-R | ||||
| PACVS (n = 191) | 13.8 | 9.9 | 18.6 | - |
| Contr. pre (n = 89) | 21.6 | 13.8 | 30.6 | <0.0001 |
| Contr. post (n = 89) | 27.9 | 20.9 | 43.2 | <0.0001 |
1 Units/mL, 2 exhibiting disease symptoms for six or more months after the last vaccination with mRNA vaccine, 3 before the first vaccination with Spikevax (Moderna), 4 six months after the second vaccination with Spikevax (Moderna), 5 not significant.